Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Mind Medicine (MindMed) Inc
N.MMED.WR
Primary Symbol:
MNMD
Alternate Symbol(s):
N.MMED.WS
|
N.MMED.WA
|
N.MMED
Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen...
drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MNMD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(15)
•••
HackerGal
X
View Profile
View Bullboard History
Comment by
HackerGal
on Oct 10, 2022 3:34pm
RE:Quiet Over Here. New Member needs Advice...
SILO WELLNESS 100%
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 05, 2022 8:36am
New Press Release - MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will...
read article.
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 04, 2022 7:30am
New Press Release - MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
- Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects -NEW YORK, Oct. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage...
read article.
(15)
•••
fTrudeau
X
View Profile
View Bullboard History
Post by
fTrudeau
on Oct 03, 2022 4:00pm
Quiet Over Here. New Member needs Advice...
In your opinion what's a better Psilocybin value play SILO WELLNESS or MIND MEDICINE? I'm thinking about selling mmed as I've been holding now since Sept 2020. At this ratio could retire
...more
(12)
•••
Rolex888
X
View Profile
View Bullboard History
Post by
Rolex888
on Sep 30, 2022 7:15am
Dilution
I wonder if O'Leary is still invested. A lot of people invested in MINDMED because of his pumping. They took full advantage of higher share price and did many equity raises early on. Rahm
...more
(1)
•••
suomynona
X
View Profile
View Bullboard History
Post by
suomynona
on Sep 29, 2022 9:16am
Cashing In Today
With 10,000 shares purchased at average $4.19 CAD yesterday, and the new offering at $4.25 USD ...is it even possible to lose?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 28, 2022 3:52pm
New Press Release - MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be NecessarySHERIDAN, Wyo., Sept. 28, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of...
read article.
(10)
•••
Investability00
X
View Profile
View Bullboard History
Post by
Investability00
on Sep 28, 2022 10:39am
The old price
would be $0.28 I never owned any and very glad.
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Sep 28, 2022 9:29am
Mind Medicine Prices $30 Million Offering At 30% Discount To
Mind Medicine has elected to destroy shareholder value in a major way this morning, pricing yet another financing despite significant money in company coffers. What’s more, is the financing is at a
...more
(33)
•••
WakeUPP
X
View Profile
View Bullboard History
Post by
WakeUPP
on Sep 28, 2022 9:13am
hey agpumper
hows that shroomboom going for ya????????????? ahahahahahahahahahhahahahah as ALWAYS when AG PUMPS is when you hit SELL
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 27, 2022 11:47pm
New Press Release - MindMed Announces Pricing of Public Offering of Common Shares and Warrants
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 27, 2022 4:18pm
New Press Release - MindMed Announces Proposed Public Offering of Common Shares
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 20, 2022 7:30am
New Press Release - MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjectsAcute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDANEW YORK, Sept. 20, 2022...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 14, 2022 7:30am
New Press Release - MindMed Announces Compliance with Nasdaq Listing Requirements
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 08, 2022 7:30am
New Press Release - MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") –- Patient dosing in Phase 2b trial ongoing for MM-120 in GAD–- MindMed currently owns and retains all clinical data and...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >